Seattle Genetics Files Antibody-Drug Conjugate BLA; Late August Approval Possible
This article was originally published in The Pink Sheet Daily
Executive Summary
The company released impressive data for SGN-35 against two advanced lymphomas in December, giving the drug a good chance at a six-month approval based on unmet need.